Vitamin B Health Claim Omits CDC Homocysteine Findings, Plaintiffs Say
This article was originally published in The Tan Sheet
Executive Summary
FDA should amend its vitamin B qualified health claim to reflect a Centers for Disease Control & Prevention statement recognizing elevated plasma homocysteine as a vascular disease risk factor, plaintiffs in the Whitaker v. Shalala case assert.
You may also be interested in...
Vitamin B Health Claim Without Total Diet Reference "Misleading" - FDA
A qualified vitamin B/vascular disease health claim that omits a statement about diets low in saturated fat and cholesterol is misleading, FDA concludes.
Vitamin B Health Claim Without Total Diet Reference "Misleading" - FDA
A qualified vitamin B/vascular disease health claim that omits a statement about diets low in saturated fat and cholesterol is misleading, FDA concludes.
Vitamin B Health Claim Without Total Diet Reference "Misleading" - FDA
A qualified vitamin B/vascular disease health claim that omits a statement about diets low in saturated fat and cholesterol is misleading, FDA concludes.